THC

Last Updated: April 11, 2024

Delta-9-tetrahydrocannabinol (THC) is the main psychoactive compound found in cannabis, and it is used both recreationally and medicinally. Evidence suggests that THC may reduce neuropathic pain and nausea and vomiting due to chemotherapy. However, THC comes with a laundry list of downsides that must be considered.

dosageDosage
research-feedResearch feed

THC is most often used for

What is THC?

Tetrahydrocannabinol (THC) is one of the major active cannabinoids found in cannabis. It is the main compound responsible for the psychoactive effects of cannabis, including changes in mental processes (e.g., thoughts, mood, and perception) that cause the feeling of being “high”.[3] While THC is found naturally in cannabis in combination with many other active compounds, like cannabidiol (CBD), some supplements and prescription medications contain isolated THC or synthetic THC analogs, which will be the focus of this page.

What are THC’s main benefits?

THC may have some therapeutic benefits on pain and chemotherapy-induced nausea and vomiting. Despite these potential benefits, THC can induce intoxication and cause other side effects that may reduce the quality of life for some people.[4][5] On the flip side, some people seek out THC recreationally for its intoxicating effects, which can include euphoria, a sense of relaxation, and altered sensory perception.

THC is likely effective for reducing nausea and vomiting in children and adults undergoing chemotherapy. The effects are superior to a placebo and potentially comparable to standard treatments, although more research is needed to confirm the latter.[6][7] While THC might reduce nausea and vomiting in other contexts, this hasn’t been thoroughly researched.

THC may also reduce chronic pain to a small or moderate degree, with most research looking at neuropathic pain of various origins.[8][9] Limited research suggests that THC may also reduce pain due to cancer or multiple sclerosis.[10] Still, how THC compares to commonly used pain relievers is not particularly clear, and when used alongside opioid analgesics, THC doesn’t seem to reduce the required dose of opioids.[11][12]

What are THC’s main drawbacks?

THC is associated with a relatively high risk of side effects that tend to be dose-dependent (occurring more often with increasing doses).

The most common side effects of THC include sedation, dizziness, confusion, impaired cognition, impaired coordination, euphoria, anxiety, paranoia, heightened sensory awareness, headache, dry mouth, increased appetite, and nausea. THC can cause intoxication and impair the ability to drive.[1][13][14]

Less often, THC may cause vomiting, hallucinations, increased heart rate, orthostatic hypotension, and psychosis (in predisposed individuals).[1] There have also been case reports linking THC with an increased risk of seizure or heart attack.[15][16][17]

If THC is inhaled via smoking or vaping, it can increase the risk of lung disease or lung injury. Vaporizing THC can minimize the production of potentially cancer-causing compounds formed through combustion; however, there is still a risk of lung injury with vaping.[3]

How does THC work?

THC exerts its effects by interacting with the body’s endocannabinoid system, which involves binding to and activating the cannabinoid receptors cannabinoid receptor 1 (CB1) and cannabinoid receptor 2 (CB2).

The brain and spinal cord are rich in CB1 receptors, which are responsible for most of THC’s effects. When THC activates CB1 receptors, it alters neurotransmission (how neurons communicate) in a way that influences many bodily functions including pain signaling, appetite, cognition, the sleep-wake cycle, and nausea and vomiting. CB2 receptors are found predominantly in immune cells, and their activation by THC may have an anti-inflammatory effect.[9][18]

What are other names for THC?
Note that THC is also known as:
  • tetrahydrocannabinol
  • Delta-9-tetrahydrocannabinol
  • Δ9-Tetrahydrocannabinol
  • Nabilone (THC analog)
  • Dronabinol (THC analog)
Dosage information

Isolated THC can be taken orally as an extract in oil, capsule, or edible form. Alternatively, THC can be inhaled through smoking or vaporizing dried cannabis or cannabis concentrates. However, the types of THC available will vary depending on the legal status of THC in your region.

The recommended dosage of THC ranges from 2.5 mg to 30 mg daily. In general, it’s recommended to start low, go slow, and stay low to reduce the risk of side effects and minimize tolerance (a reduced response to the drug after repeated use).[1] This might look like starting at a dose of 2.5–5 mg and increasing slowly (every few days or as tolerated) until the desired therapeutic effect is achieved but side effects are kept to a minimum. If using a prescription medication containing a synthetic version of THC, the dosing may not necessarily be equivalent to natural THC.

THC taken orally will have a slower onset (1–3 hours) than inhaled THC, which has a rapid onset (5–10 minutes).[2]

You can estimate the dose of THC in dried cannabis based on the percent of THC in the product. Simply multiply the total dried weight in milligrams (1 gram = 1,000 milligrams) by the percentage of THC in the product. For example, if you have 0.25 g (250 mg) of dried cannabis with 10% THC, it will contain 25 mg of THC (250 mg x 0.10).

Supplements Demystified: Get Our Unbiased, Evidence-Based Guide

Don't miss out on the latest research

Update History
2024-04-11 00:30:03

Full page update

major

We created brand new FAQs for the THC page! The update includes information about what THC is, how it works, and the potential benefits and risks of using THC.

References
  1. ^Campos DA, Mendivil EJ, Romano M, García M, Martínez MEA Systematic Review of Medical Cannabinoids Dosing in Human.Clin Ther.(2022-Dec)
  2. ^Chayasirisobhon SMechanisms of Action and Pharmacokinetics of Cannabis.Perm J.(2020-Dec)
  3. ^Poyatos L, Pérez-Acevedo AP, Papaseit E, Pérez-Mañá C, Martin S, Hladun O, Siles A, Torrens M, Busardo FP, Farré MOral Administration of Cannabis and Δ-9-tetrahydrocannabinol (THC) Preparations: A Systematic Review.Medicina (Kaunas).(2020 Jun 23)
  4. ^Vera Belgers, Jantine G Röttgering, Linda Douw, Martin Klein, Johannes C F Ket, Peter M van de Ven, Thomas Würdinger, Myra E van Linde, Johanna M Niers, Markus Weber, Marcel G Olde Rikkert, Jose Lopez-Sendon, Oscar Arrieta, Kristina B Svendsen, Marcos H N Chagas, Carlos M O de Almeida, Mathilde C M Kouwenhoven, Philip C de Witt HamerCannabinoids to Improve Health-Related Quality of Life in Patients with Neurological or Oncological Disease: A Meta-AnalysisCannabis Cannabinoid Res.(2022 Jul 21)
  5. ^Wang J, Wang Y, Tong M, Pan H, Li DMedical Cannabinoids for Cancer Cachexia: A Systematic Review and Meta-Analysis.Biomed Res Int.(2019)
  6. ^Chow R, Valdez C, Chow N, Zhang D, Im J, Sodhi E, Lock MOral cannabinoid for the prophylaxis of chemotherapy-induced nausea and vomiting-a systematic review and meta-analysis.Support Care Cancer.(2020 May)
  7. ^Chhabra M, Ben-Eltriki M, Paul A, Lê ML, Herbert A, Oberoi S, Bradford N, Bowers A, Rassekh SR, Kelly LECannabinoids for symptom management in children with cancer: A systematic review and meta-analysis.Cancer.(2023 Nov 15)
  8. ^Bilbao A, Spanagel RMedical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications.BMC Med.(2022 Aug 19)
  9. ^Bradley Sainsbury, Jared Bloxham, Masoumeh Hassan Pour, Mariela Padilla, Reyes EncisoEfficacy of cannabis-based medications compared to placebo for the treatment of chronic neuropathic pain: a systematic review with meta-analysisJ Dent Anesth Pain Med.(2021 Dec)
  10. ^Zeng F, Wade A, Harbert K, Patel S, Holley JS, Dehghanpuor CK, Hopwood T, Marino S, Sophocleous A, Idris AIClassical cannabinoid receptors as target in cancer-induced bone pain: a systematic review, meta-analysis and bioinformatics validation.Sci Rep.(2024 Mar 9)
  11. ^Wang L, Hong PJ, May C, Rehman Y, Oparin Y, Hong CJ, Hong BY, AminiLari M, Gallo L, Kaushal A, Craigie S, Couban RJ, Kum E, Shanthanna H, Price I, Upadhye S, Ware MA, Campbell F, Buchbinder R, Agoritsas T, Busse JWMedical cannabis or cannabinoids for chronic non-cancer and cancer related pain: a systematic review and meta-analysis of randomised clinical trials.BMJ.(2021 Sep 8)
  12. ^Nielsen S, Picco L, Murnion B, Winters B, Matheson J, Graham M, Campbell G, Parvaresh L, Khor KE, Betz-Stablein B, Farrell M, Lintzeris N, Le Foll BOpioid-sparing effect of cannabinoids for analgesia: an updated systematic review and meta-analysis of preclinical and clinical studies.Neuropsychopharmacology.(2022-Jun)
  13. ^Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, Keurentjes JC, Lang S, Misso K, Ryder S, Schmidlkofer S, Westwood M, Kleijnen JCannabinoids for Medical Use: A Systematic Review and Meta-analysisJAMA.(2015 Jun 23-30)
  14. ^Rosager EV, Møller C, Sjögren MTreatment studies with cannabinoids in anorexia nervosa: a systematic review.Eat Weight Disord.(2021-Mar)
  15. ^Fogang YF, Camara M, Mbonda PC, Toffa D, Touré KLate onset epilepsy associated with marijuana abuse: a case report with MRI findings.Pan Afr Med J.(2014)
  16. ^Emoto J, Weeks K, Kallail KJAccidental Acute Cannabis Intoxication Presenting as Seizure in Pediatrics Patients.Kans J Med.(2020)
  17. ^Seffah KD, Kumar M, Naveen N, Pachchipulusu VK, Paudel Y, Patel A, Najam B, Desai HN, Illango J, Hamid PTo Weed or Not to Weed: A Systematic Review Exploring the Potential for Cannabis Use in Cardiovascular Disease, Mental Health and Pain Management.Cureus.(2023-Jun)
  18. ^Turcotte C, Blanchet MR, Laviolette M, Flamand NThe CB receptor and its role as a regulator of inflammation.Cell Mol Life Sci.(2016-Dec)
  19. ^Volkow ND, Han B, Compton WM, McCance-Katz EFSelf-reported Medical and Nonmedical Cannabis Use Among Pregnant Women in the United States.JAMA.(2019 Jul 9)
  20. ^Sorkhou M, Singla DR, Castle DJ, George TPBirth, cognitive and behavioral effects of intrauterine cannabis exposure in infants and children: A systematic review and meta-analysis.Addiction.(2024 Mar)
  21. ^Baía I, Domingues RMSMThe Effects of Cannabis Use during Pregnancy on Low Birth Weight and Preterm Birth: A Systematic Review and Meta-analysis.Am J Perinatol.(2024 Jan)
  22. ^Moss MJ, Bushlin I, Kazmierczak S, Koop D, Hendrickson RG, Zuckerman KE, Grigsby TMCannabis use and measurement of cannabinoids in plasma and breast milk of breastfeeding mothers.Pediatr Res.(2021 Oct)
  23. ^Josan C, Shiplo S, Fusch G, Raha S, Shea AKCannabis use during lactation may alter the composition of human breast milk.Pediatr Res.(2023 Jun)
  24. ^"Cannabis". In Drugs and Lactation Database (LactMed®); USA: National Institute of Child Health and Human Development, updated 2023 Nov, cited 2024 Apr(2006)
  25. ^Petrilli K, Ofori S, Hines L, Taylor G, Adams S, Freeman TPAssociation of cannabis potency with mental ill health and addiction: a systematic review.Lancet Psychiatry.(2022 Sep)
  26. ^Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TECannabis use in adolescence and risk for adult psychosis: longitudinal prospective study.BMJ.(2002 Nov 23)
  27. ^Fergusson DM, Horwood LJ, Ridder EMTests of causal linkages between cannabis use and psychotic symptoms.Addiction.(2005 Mar)
  28. ^Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis GSelf reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study.BMJ.(2002 Nov 23)
  29. ^van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux HCannabis use and psychosis: a longitudinal population-based study.Am J Epidemiol.(2002 Aug 15)
  30. ^Kuepper R, van Os J, Lieb R, Wittchen HU, Höfler M, Henquet CContinued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study.BMJ.(2011-Mar-01)
  31. ^Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, Harrington H, Taylor A, Arseneault L, Williams B, Braithwaite A, Poulton R, Craig IWModeration of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction.Biol Psychiatry.(2005-May-15)
  32. ^Bosnjak Kuharic D, Markovic D, Brkovic T, Jeric Kegalj M, Rubic Z, Vuica Vukasovic A, Jeroncic A, Puljak LCannabinoids for the treatment of dementia.Cochrane Database Syst Rev.(2021-Sep-17)
  33. ^Florindo Stella, Leandro C Lane Valiengo, Vanessa J R de Paula, Carlos Augusto de Mendonça Lima, Orestes V ForlenzaMedical cannabinoids for treatment of neuropsychiatric symptoms in dementia: a systematic reviewTrends Psychiatry Psychother.(2021 Oct-Dec)
  34. ^Zhornitsky S, Pelletier J, Assaf R, Giroux S, Li CR, Potvin SAcute effects of partial CB receptor agonists on cognition - A meta-analysis of human studies.Prog Neuropsychopharmacol Biol Psychiatry.(2021-Jan-10)
  35. ^Steardo L Jr, Carbone EA, Menculini G, Moretti P, Steardo L, Tortorella AEndocannabinoid System as Therapeutic Target of PTSD: A Systematic Review.Life (Basel).(2021 Mar 9)
  36. ^Lotfinia S, Afshar A, Yaseri A, Olff M, Quidé YFunctional brain changes after alternative pharmacological interventions in posttraumatic stress disorder: A systematic review of clinical trials.Brain Behav.(2023 Dec)
  37. ^Anastasia S Suraev, Nathaniel S Marshall, Ryan Vandrey, Danielle McCartney, Melissa J Benson, Iain S McGregor, Ronald R Grunstein, Camilla M HoyosCannabinoid therapies in the management of sleep disorders: A systematic review of preclinical and clinical studiesSleep Med Rev.(2020 May 16)
  38. ^Jane Metrik, Angela K Stevens, Rachel L Gunn, Brian Borsari, Kristina M JacksonCannabis use and posttraumatic stress disorder: prospective evidence from a longitudinal study of veteransPsychol Med.(2020 Jun 17)
  39. ^Zach Walsh, Robert Callaway, Lynne Belle-Isle, Rielle Capler, Robert Kay, Philippe Lucas, Susan HoltzmanCannabis for therapeutic purposes: patient characteristics, access, and reasons for useInt J Drug Policy.(2013 Nov)
  40. ^Velzeboer R, Malas A, Boerkoel P, Cullen K, Hawkins M, Roesler J, Lai WWCannabis dosing and administration for sleep: a systematic review.Sleep.(2022-Nov-09)
  41. ^Bhagavan C, Kung S, Doppen M, John M, Vakalalabure I, Oldfield K, Braithwaite I, Newton-Howes GCannabinoids in the Treatment of Insomnia Disorder: A Systematic Review and Meta-Analysis.CNS Drugs.(2020-Dec)
  42. ^Born JSlow-wave sleep and the consolidation of long-term memory.World J Biol Psychiatry.(2010-Jun)
  43. ^M Haney, A S Ward, S D Comer, R W Foltin, M W FischmanAbstinence symptoms following oral THC administration to humansPsychopharmacology (Berl).(1999 Feb)
  44. ^Budney AJ, Hughes JRThe cannabis withdrawal syndrome.Curr Opin Psychiatry.(2006 May)
  45. ^Preuss UW, Watzke AB, Zimmermann J, Wong JW, Schmidt COCannabis withdrawal severity and short-term course among cannabis-dependent adolescent and young adult inpatients.Drug Alcohol Depend.(2010 Jan 15)
  46. ^Velayudhan L, McGoohan K, Bhattacharyya SSafety and tolerability of natural and synthetic cannabinoids in adults aged over 50 years: A systematic review and meta-analysis.PLoS Med.(2021 Mar)
  47. ^Broyd SJ, van Hell HH, Beale C, Yücel M, Solowij NAcute and Chronic Effects of Cannabinoids on Human Cognition-A Systematic Review.Biol Psychiatry.(2016 Apr 1)
  48. ^Information for Health Care Professionals: Cannabis (marihuana, marijuana) and the cannabinoids; Health Canada, cited February 2025(October 2018)
  49. ^Renard J, Krebs MO, Le Pen G, Jay TMLong-term consequences of adolescent cannabinoid exposure in adult psychopathology.Front Neurosci.(2014)
  50. ^Ortiz-Medina MB, Perea M, Torales J, Ventriglio A, Vitrani G, Aguilar L, Roncero CCannabis consumption and psychosis or schizophrenia development.Int J Soc Psychiatry.(2018 Nov)
  51. ^Preuss UW, Huestis MA, Schneider M, Hermann D, Lutz B, Hasan A, Kambeitz J, Wong JWM, Hoch ECannabis Use and Car Crashes: A Review.Front Psychiatry.(2021)
  52. ^Danielle McCartney, Thomas R Arkell, Christopher Irwin, Iain S McGregorDetermining the magnitude and duration of acute Δ 9-tetrahydrocannabinol (Δ 9-THC)-induced driving and cognitive impairment: A systematic and meta-analytic reviewNeurosci Biobehav Rev.(2021 Jan 23)
  53. ^Asbridge M, Hayden JA, Cartwright JLAcute cannabis consumption and motor vehicle collision risk: systematic review of observational studies and meta-analysis.BMJ.(2012 Feb 9)
  54. ^Semple DM, McIntosh AM, Lawrie SMCannabis as a risk factor for psychosis: systematic review.J Psychopharmacol.(2005 Mar)
  55. ^Solmi M, De Toffol M, Kim JY, Choi MJ, Stubbs B, Thompson T, Firth J, Miola A, Croatto G, Baggio F, Michelon S, Ballan L, Gerdle B, Monaco F, Simonato P, Scocco P, Ricca V, Castellini G, Fornaro M, Murru A, Vieta E, Fusar-Poli P, Barbui C, Ioannidis JPA, Carvalho AF, Radua J, Correll CU, Cortese S, Murray RM, Castle D, Shin JI, Dragioti EBalancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies.BMJ.(2023 Aug 30)
  56. ^Schoeler T, Monk A, Sami MB, Klamerus E, Foglia E, Brown R, Camuri G, Altamura AC, Murray R, Bhattacharyya SContinued versus discontinued cannabis use in patients with psychosis: a systematic review and meta-analysis.Lancet Psychiatry.(2016 Mar)
  57. ^Rabin RA, Zakzanis KK, George TPThe effects of cannabis use on neurocognition in schizophrenia: a meta-analysis.Schizophr Res.(2011 May)
  58. ^Myles N, Newall H, Nielssen O, Large MThe association between cannabis use and earlier age at onset of schizophrenia and other psychoses: meta-analysis of possible confounding factors.Curr Pharm Des.(2012)
  59. ^Guy Hindley, Katherine Beck, Faith Borgan, Cedric E Ginestet, Robert McCutcheon, Daniel Kleinloog, Suhas Ganesh, Rajiv Radhakrishnan, Deepak Cyril D'Souza, Oliver D HowesPsychiatric Symptoms Caused by Cannabis Constituents: A Systematic Review and Meta-AnalysisLancet Psychiatry.(2020 Apr)
  60. ^Ganesh S, Cortes-Briones J, Ranganathan M, Radhakrishnan R, Skosnik PD, D'Souza DCPsychosis-Relevant Effects of Intravenous Delta-9-Tetrahydrocannabinol: A Mega Analysis of Individual Participant-Data from Human Laboratory Studies.Int J Neuropsychopharmacol.(2020 Dec 3)
  61. ^Martinasek MP, McGrogan JB, Maysonet AA Systematic Review of the Respiratory Effects of Inhalational Marijuana.Respir Care.(2016 Nov)
  62. ^Kalininskiy A, Bach CT, Nacca NE, Ginsberg G, Marraffa J, Navarette KA, McGraw MD, Croft DPE-cigarette, or vaping, product use associated lung injury (EVALI): case series and diagnostic approach.Lancet Respir Med.(2019 Dec)
  63. ^Richards JR, Bing ML, Moulin AK, Elder JW, Rominski RT, Summers PJ, Laurin EGCannabis use and acute coronary syndrome.Clin Toxicol (Phila).(2019 Oct)
  64. ^Latif Z, Garg NThe Impact of Marijuana on the Cardiovascular System: A Review of the Most Common Cardiovascular Events Associated with Marijuana Use.J Clin Med.(2020 Jun 19)
  65. ^Rikinkumar S Patel, Saher H Kamil, Ramya Bachu, Archana Adikey, Virendrasinh Ravat, Mandeep Kaur, William E Tankersley, Hemant GoyalMarijuana use and acute myocardial infarction: A systematic review of published cases in the literatureTrends Cardiovasc Med.(2020 Jul)
  66. ^Robert L Page 2nd, Larry A Allen, Robert A Kloner, Colin R Carriker, Catherine Martel, Alanna A Morris, Mariann R Piano, Jamal S Rana, Jorge F Saucedo, American Heart Association Clinical Pharmacology Committee and Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; Council on Basic Cardiovascular Sciences; Council on Cardiovascular and Stroke Nursing; Council on Epidemiology and Prevention; Council on Lifestyle and Cardiometabolic Health; and Council on Quality of Care and Outcomes ResearchMedical Marijuana, Recreational Cannabis, and Cardiovascular Health: A Scientific Statement From the American Heart AssociationCirculation.(2020 Sep 8)
  67. ^Lindsay AC, Foale RA, Warren O, Henry JACannabis as a precipitant of cardiovascular emergencies.Int J Cardiol.(2005 Sep 30)
  68. ^Saunders A, Stevenson RSMarijuana Lollipop-Induced Myocardial Infarction.Can J Cardiol.(2019 Feb)
  69. ^Aronow WS, Cassidy JEffect of marihuana and placebo-marihuana smoking on angina pectoris.N Engl J Med.(1974 Jul 11)
  70. ^Aronow WS, Cassidy JEffect of smoking marihuana and of a high-nicotine cigarette on angina pectoris.Clin Pharmacol Ther.(1975 May)
  71. ^Ákos Bajtel, Tivadar Kiss, Barbara Tóth, Szabolcs Kiss, Péter Hegyi, Nóra Vörhendi, Boglárka Csupor-Löffler, Noémi Gede, Judit Hohmann, Dezső CsuporThe Safety of Dronabinol and Nabilone: A Systematic Review and Meta-Analysis of Clinical TrialsPharmaceuticals (Basel).(2022 Jan 14)
  72. ^Pisani S, McGoohan K, Velayudhan L, Bhattacharyya SSafety and Tolerability of Natural and Synthetic Cannabinoids in Older Adults: A Systematic Review and Meta-Analysis of Open-Label Trials and Observational Studies.Drugs Aging.(2021 Oct)
  73. ^Illsley NP, Lin HY, Verkman ASLipid-phase structure in epithelial cell membranes: comparison of renal brush border and basolateral membranes.Biochemistry.(1988 Mar 22)
  74. ^Sultan SR, Millar SA, O'Sullivan SE, England TJA Systematic Review and Meta-Analysis of the In Vivo Haemodynamic Effects of Δ⁸-Tetrahydrocannabinol.Pharmaceuticals (Basel).(2018 Jan 31)
  75. ^Freeman AM, Petrilli K, Lees R, Hindocha C, Mokrysz C, Curran HV, Saunders R, Freeman TPHow does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic review.Neurosci Biobehav Rev.(2019 Dec)
  76. ^Lile JA, Kelly TH, Hays LRThe reinforcing, self-reported performance and physiological effects of Delta9-tetrahydrocannabinol, triazolam, hydromorphone, and methylphenidate in cannabis users.Behav Pharmacol.(2010 Feb)
  77. ^Ng T, Keshock MCTetrahydrocannabinol (THC).StatPearls.(2025 Jan)
  78. ^Benowitz NL, Jones RTProlonged delta-9-tetrahydrocannabinol ingestion. Effects of sympathomimetic amines and autonomic blockades.Clin Pharmacol Ther.(1977 Mar)
  79. ^Velayudhan L, McGoohan KL, Bhattacharyya SEvaluation of THC-Related Neuropsychiatric Symptoms Among Adults Aged 50 Years and Older: A Systematic Review and Metaregression Analysis.JAMA Netw Open.(2021 Feb 1)
  80. ^van Dam CJ, van der Schrier R, van Velzen M, van Lemmen M, Simons P, Kuijpers KWK, Jansen S, Kowal MA, Olofsen E, Kramers C, Dahan A, Niesters MInhaled Δ(9)-tetrahydrocannabinol does not enhance oxycodone-induced respiratory depression: randomised controlled trial in healthy volunteers.Br J Anaesth.(2023 Apr)
  81. ^Wickens CM, Wright M, Mann RE, Brands B, Di Ciano P, Stoduto G, Fares A, Matheson J, George TP, Rehm J, Shuper PA, Sproule B, Samohkvalov A, Huestis MA, Le Foll BSeparate and combined effects of alcohol and cannabis on mood, subjective experience, cognition and psychomotor performance: A randomized trial.Prog Neuropsychopharmacol Biol Psychiatry.(2022 Aug 30)
  82. ^Manno JE, Kiplinger GF, Scholz N, Forney RBThe influence of alcohol and marihuana on motor and mental performance.Clin Pharmacol Ther.(1971 Mar-Apr)
  83. ^Dalton WS, Martz R, Lemberger L, Rodda BE, Forney RBEffects of marihuana combined with secobarbital.Clin Pharmacol Ther.(1975 Sep)
  84. ^Johnstone RE, Lief PL, Kulp RA, Smith TCCombination of delta9-tetrahydrocannabinol with oxymorphone or pentobarbital: Effects on ventilatory control and cardiovascular dynamics.Anesthesiology.(1975 Jun)
  85. ^Sofia RD, Knobloch LCThe interaction of 9 -tetrahydrocannabinol pretreatment with various sedative-hypnotic drugs.Psychopharmacologia.(1973 May 21)
  86. ^Schnakenberg Martin AM, Flynn LT, Sefik E, Luddy C, Cortes-Briones J, Skosnik PD, Pittman B, Ranganathan M, D'Souza DCPreliminary study of the interactive effects of THC and ethanol on self-reported ability and simulated driving, subjective effects, and cardiovascular responses.Psychopharmacology (Berl).(2023 Jun)
  87. ^Rowley KM, Kopf GS, Hellenbrand W, Kleinman CS, Downing SEAtrioventricular canal with intact atrial septum.Am Heart J.(1988 Apr)
  88. ^Ronen A, Chassidim HS, Gershon P, Parmet Y, Rabinovich A, Bar-Hamburger R, Cassuto Y, Shinar DThe effect of alcohol, THC and their combination on perceived effects, willingness to drive and performance of driving and non-driving tasks.Accid Anal Prev.(2010 Nov)
  89. ^Chesher GB, Franks HM, Hensley VR, Hensley WJ, Jackson DM, Starmer GA, Teo RKThe interaction of ethanol and delta9-tetrahydrocannabinol in man: effects on perceptual, cognitive and motor functions.Med J Aust.(1976 Jul 31)
  90. ^Freemon FR, Rosenblatt JE, EL-Yousef MKInteraction of physostigmine and delta-9-tetrahydrocannabinol in man.Clin Pharmacol Ther.(1975 Feb)
  91. ^Mannion VCase report: adverse effects of taking tricyclic antidepressants and smoking marijuana.Can Fam Physician.(1999 Nov)
  92. ^Wilens TE, Biederman J, Spencer TJCase study: adverse effects of smoking marijuana while receiving tricyclic antidepressants.J Am Acad Child Adolesc Psychiatry.(1997 Jan)
  93. ^Hillard JR, Vieweg WVMarked sinus tachycardia resulting from the synergistic effects of marijuana and nortriptyline.Am J Psychiatry.(1983 May)
  94. ^Kollins SH, Schoenfelder EN, English JS, Holdaway A, Van Voorhees E, O'Brien BR, Dew R, Chrisman AKAn exploratory study of the combined effects of orally administered methylphenidate and delta-9-tetrahydrocannabinol (THC) on cardiovascular function, subjective effects, and performance in healthy adults.J Subst Abuse Treat.(2015 Jan)
  95. ^Brown GW, Bellnier TJ, Janda M, Miskowitz KΔ-9-tetrahydrocannabinol dose increase leads to warfarin drug interaction and elevated INR.J Am Pharm Assoc (2003).(2021 Jan-Feb)
  96. ^Smythe MA, Wu W, Garwood CLAnticoagulant drug-drug interactions with cannabinoids: A systematic review.Pharmacotherapy.(2023 Dec)
  97. ^Stout SM, Cimino NMExogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic reviewDrug Metab Rev.(2014 Feb)
  98. ^Bansal S, Zamarripa CA, Spindle TR, Weerts EM, Thummel KE, Vandrey R, Paine MF, Unadkat JDEvaluation of Cytochrome P450-Mediated Cannabinoid-Drug Interactions in Healthy Adult Participants.Clin Pharmacol Ther.(2023 Sep)
  99. ^Sachse-Seeboth C, Pfeil J, Sehrt D, Meineke I, Tzvetkov M, Bruns E, Poser W, Vormfelde SV, Brockmöller JInterindividual variation in the pharmacokinetics of Delta9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9.Clin Pharmacol Ther.(2009 Mar)
  100. ^Herdegen T, Cascorbi IDrug Interactions of Tetrahydrocannabinol and Cannabidiol in Cannabinoid Drugs.Dtsch Arztebl Int.(2023 Dec 8)
  101. ^Beyersdorf F, Sarai K, Wendt T, Eckel L, Schneider M, Kubitzky WProlonged abnormalities of LV regional wall motion after normal reperfusion in patients with preoperative cardiogenic shock.Thorac Cardiovasc Surg.(1990 Jun)
  102. ^Stott C, White L, Wright S, Wilbraham D, Guy GA Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteersSpringerplus.(2013 May 24)
  103. ^Nasrin S, Watson CJW, Perez-Paramo YX, Lazarus PCannabinoid Metabolites as Inhibitors of Major Hepatic CYP450 Enzymes, with Implications for Cannabis-Drug Interactions.Drug Metab Dispos.(2021 Dec)
  104. ^Bansal S, Maharao N, Paine MF, Unadkat JDPredicting the Potential for Cannabinoids to Precipitate Pharmacokinetic Drug Interactions via Reversible Inhibition or Inactivation of Major Cytochromes P450.Drug Metab Dispos.(2020 Oct)
  105. ^Doohan PT, Oldfield LD, Arnold JC, Anderson LLCannabinoid Interactions with Cytochrome P450 Drug Metabolism: a Full-Spectrum Characterization.AAPS J.(2021 Jun 28)
  106. ^Kosel BW, Aweeka FT, Benowitz NL, Shade SB, Hilton JF, Lizak PS, Abrams DIThe effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir.AIDS.(2002 Mar 8)
  107. ^Tournier N, Chevillard L, Megarbane B, Pirnay S, Scherrmann JM, Declèves XInteraction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2).Int J Neuropsychopharmacol.(2010 Aug)
  108. ^Chen X, Unadkat JD, Mao QTetrahydrocannabinol and Its Major Metabolites Are Not (or Are Poor) Substrates or Inhibitors of Human P-Glycoprotein ATP-Binding Cassette (ABC) B1 and Breast Cancer Resistance Protein (ABCG2).Drug Metab Dispos.(2021 Oct)
  109. ^Brzozowska NI, de Tonnerre EJ, Li KM, Wang XS, Boucher AA, Callaghan PD, Kuligowski M, Wong A, Arnold JCThe Differential Binding of Antipsychotic Drugs to the ABC Transporter P-Glycoprotein Predicts Cannabinoid-Antipsychotic Drug Interactions.Neuropsychopharmacology.(2017 Oct)
  110. ^Arnold JC, Hone P, Holland ML, Allen JDCB2 and TRPV1 receptors mediate cannabinoid actions on MDR1 expression in multidrug resistant cells.Pharmacol Rep.(2012)
  111. ^Zamarripa CA, Spindle TR, Surujunarain R, Weerts EM, Bansal S, Unadkat JD, Paine MF, Vandrey RAssessment of Orally Administered Δ9-Tetrahydrocannabinol When Coadministered With Cannabidiol on Δ9-Tetrahydrocannabinol Pharmacokinetics and Pharmacodynamics in Healthy Adults: A Randomized Clinical Trial.JAMA Netw Open.(2023 Feb 1)
  112. ^Englund A, Oliver D, Chesney E, Chester L, Wilson J, Sovi S, De Micheli A, Hodsoll J, Fusar-Poli P, Strang J, Murray RM, Freeman TP, McGuire PDoes cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratios.Neuropsychopharmacology.(2023 May)
  113. ^Yamaori S, Koeda K, Kushihara M, Hada Y, Yamamoto I, Watanabe KComparison in the in vitro inhibitory effects of major phytocannabinoids and polycyclic aromatic hydrocarbons contained in marijuana smoke on cytochrome P450 2C9 activity.Drug Metab Pharmacokinet.(2012)
  114. ^Karen Oldfield, John Ryan, Marjan Doppen, Stacey Kung, Irene Braithwaite, Giles Newton-HowesA systematic review of the label accuracy of cannabinoid-based products in regulated markets: is what's on the label what's in the product?Australas Psychiatry.(2021 Feb)
  115. ^Schwabe AL, Johnson V, Harrelson J, McGlaughlin MEUncomfortably high: Testing reveals inflated THC potency on retail Cannabis labels.PLoS One.(2023)
  116. ^Raber JC, Elzinga S, Kaplan CUnderstanding dabs: contamination concerns of cannabis concentrates and cannabinoid transfer during the act of dabbing.J Toxicol Sci.(2015 Dec)
  117. ^Qian L, Beers JL, Jackson KD, Zhou ZCBD and THC in Special Populations: Pharmacokinetics and Drug-Drug Interactions.Pharmaceutics.(2024 Apr 1)
  118. ^Astley SJ, Little REMaternal marijuana use during lactation and infant development at one year.Neurotoxicol Teratol.(1990 Mar-Apr)
  119. ^Desai R, Fong HK, Shah K, Kaur VP, Savani S, Gangani K, Damarlapally N, Goyal HRising Trends in Hospitalizations for Cardiovascular Events among Young Cannabis Users (18-39 Years) without Other Substance Abuse.Medicina (Kaunas).(2019 Aug 5)